Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines

•Beta blockers should be continued for 1 year after acute coronary syndrome and be reassessed after 1 year; the decision for continued therapy should be based on comorbidities.•Combination lipid-lowering therapy should be used to achieve a low-density lipoprotein cholesterol concentration of at least less than 70 mg/dL in very high risk atherosclerotic cardiovascular disease patients.•Social determinants of health dramatically affect outcomes and the care team is essential in addressing these factors to optimize care.